Are there plans for further studies?
There are several ongoing and planned studies looking at the effects of shingles vaccination in different
groups.
Where can I find more information about this study?
The detailed title for this research study is:
A phase III, open label, multicenter study to evaluate the impact of reactogenicity on Quality of Life (QoL),
after intramuscular administration of GSK Biologicals’ candidate Herpes Zoster subunit (HZ/su) vaccine
(GSK1437173A) in adults ≥ 50 years of age.
Organization Website Study Number
United States National Institutes of www.clinicaltrials.gov NCT02979639
Health (NIH)
Your doctor can help you understand more about this study and the results. You should not make
changes to your care based on the results of this or any single study. Keep taking your current
treatment unless instructed by your doctor.
This document was developed and approved by GSK on <<insert approval date>>. The information in this
summary does not include additional information available after this date.
Use of the data and information contained in this document is unrestricted, provided that it may not be used in applications
by others for regulatory approval of a product. While not required, when using these data, we ask that proper credit or
attribution of GSK as the source of the data be given. GSK disclaims liability for all uses of the data by users of this document,
to the fullest extent permitted by applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are
waived, licensed or otherwise affected.
For readers of this document in text form, the websites associated with the hyperlinks above are:
US NIH/clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02979639?term=204928&rank=1